Treatment
Crosstalk with lung fibroblasts shapes the growth and therapeutic response of mesothelioma cells
Cell Death and Disease 2023 November 8 [Link] Yakinthi Chrisochoidou, Rajat Roy, Pooyeh Farahmand, Guadalupe Gonzalez, Jennifer Doig, Lukas Krasny, Ella F Rimmer, Anne E Willis, Marion MacFarlane, Paul H Huang, Neil O Carragher, Alison F Munro, Daniel J Murphy, Kirill Veselkov, Michael J Seckl, Miriam F Moffatt, William O C Cookson, Olivier E Pardo…
Read MoreImpact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC
Annals of Surgical Oncology 2023 January [Link] Ambarish Chatterjee, Shigeki Kusamura, Dario Baratti, Marcello Guaglio, Luigi Battaglia, Marcello Deraco Abstract Background: The available data on the role of perioperative systemic chemotherapy (SC) for diffuse malignant peritoneal mesothelioma (DMPM) patients undergoing (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is heterogeneous and unstandardized. This study aimed to evaluate…
Read MoreMalignant Mesothelioma of the Testes with Retroperitoneal Recurrence and Resection in an 80-Year-Old Male and Review of the Literature
Case Reports in Oncology 2023 August 22 [Link] W C Ian Janes, Sohaib Al-Asaaed, Paul H Johnston Abstract Malignant mesothelioma of the testes is an aggressive, yet rare urogenital malignancy, accounting for an infinitesimally small number of oncologic diagnoses. This infrequent occurrence is accompanied by a relative lack of knowledge surrounding this disease, thus limiting…
Read MoreDevelopment of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors
Nature Communications 2023 November 3 [Link] Jacopo Chiaro, Gabriella Antignani, Sara Feola, Michaela Feodoroff, Beatriz Martins, Hanne Cojoc, Salvatore Russo, Manlio Fusciello, Firas Hamdan, Valentina Ferrari, Daniele Ciampi, Ilkka Ilonen, Jari Räsänen, Mikko Mäyränpää, Jukka Partanen, Satu Koskela, Jarno Honkanen, Jussi Halonen, Lukasz Kuryk, Maria Rescigno, Mikaela Grönholm, Rui M Branca, Janne Lehtiö, Vincenzo Cerullo…
Read MoreCo-existing pericardial and pleural malignant mesothelioma responding well to nedaplatin and pemetrexed: a case report
AME Case Reports 2023 August 3 [Link] Mindan Wu, Zhixuan Li, Junfu Cai, Xianyang Zhong, Wenchuan Zheng, Shuhan Wu, Maohuang Lin, Qichuan Zhang Abstract Background: Malignant mesothelioma (MM) is a rare cancer with poor prognosis. It is less common that two serosal cavities are involved when the patient seeks medical attention firstly. The current first-line…
Read MorePleural mesothelioma: a snapshot of emerging drug targets and opportunities for non-surgical therapeutic advancement
Expert Opinion on Therapeutic Targets 2023 October 30 [Link] Jean-Baptiste Assié, Didier Jean Abstract Introduction: Pleural mesothelioma is a rare and aggressive cancer originating in the pleura, with a devastating prognosis and limited treatment options. There have been significant advancements in the management of this disease in recent years. Since 2021, nivolumab and ipilimumab immune…
Read MoreThe prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – A prospective cohort study
Journal of Medical Imaging and Radiation Oncology 2023 October 29 [Link] Isaac J May, Anna K Nowak, Roslyn J Francis, Martin A Ebert, Satvinder S Dhaliwal Abstract Introduction: Malignant pleural mesothelioma is difficult to prognosticate. F18-Fluorodeoxyglucose positron emission tomography (FDG PET) shows promise for response assessment but is confounded by talc pleurodesis. F18-Fluorothymidine (FLT) PET…
Read MorePerioperative discordance in mesothelioma cell type after pleurectomy/decortication-a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
Interdisciplinary Cardiovascular Thoracic Surgery 2023 November 2 [Link] Luigi Ventura, Michelle Lee, Ralitsa Baranowski, Joanne Hargrave, Michael Sheaff, David Waller Abstract Objectives: The goal was to evaluate the accuracy of preoperative histological assessment and the factors affecting the accuracy and the subsequent effect on postoperative survival after surgical treatment for malignant pleural mesothelioma (MPM). Methods:…
Read MoreFunctional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor
Cancer Immunology, Immunotherapy 2023 October 18 [Link] Derrick McCarthy, Michael Lofgren, Amy Watt, Holly Horton, Philippe Kieffer-Kwon, Jian Ding, Sebastian Kobold, Patrick A Baeuerle, Robert Hofmeister, Dario A Gutierrez, Robert Tighe Abstract T cells expressing a mesothelin (MSLN)-specific T cell receptor fusion construct (TRuC®), called TC-210, have demonstrated robust antitumor activity in preclinical models of…
Read MoreComprehensive bioinformatics analysis of the role of VWF in the tumor microenvironment of malignant mesothelioma
Medicine 2023 October 13 [Link] Jiren Weng, Jing Chen Abstract To explore the influence and effect of tumor microenvironment on the development of malignant mesothelioma using machine learning methods. 87 open cases were downloaded from the Cancer Genome Atlas database including transcriptome data, clinical data, and mutation data. The immune, stromal, and estimate scores were…
Read More